Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma



Status:Recruiting
Conditions:Hematology, Hematology, Hematology
Therapuetic Areas:Hematology
Healthy:No
Age Range:18 - Any
Updated:3/23/2019
Start Date:March 11, 2019
End Date:March 11, 2022
Contact:Christine Duran
Email:Duran_C@med.usc.edu
Phone:323-865-0371

Use our guide to learn which trials are right for you!

Phase II Multi-Institutional Study of Low-Dose (2Gy x 2) Palliative Radiotherapy in the Treatment of Symptomatic Bone Metastases From Multiple Myeloma

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in
patients with multiple myeloma that has spread to the bone. Radiation therapy uses high
energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink
tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not
interfere as much with the timing of chemotherapy, and may have less chance for short term or
long-term side effects from the radiation.

PRIMARY OBJECTIVES:

I. To determine whether treatment with 2 Gy x 2 to a painful myeloma bone lesion achieves
patient-reported pain reduction comparable to current standard of care at 4 weeks.

SECONDARY OBJECTIVES:

I. To assess quality of life (QOL) in patients treated with 2 Gy x 2 to painful myeloma bone
lesions.

II. To quantify analgesia use/reduction following 2 Gy x 2 to a painful myeloma bone lesion.
All opioid analgesia use will be converted into morphine equivalent in order to compare
across the entire population.

III. To measure time to pain relief and duration of pain relief with 2 Gy x 2.

EXPLORATORY OBJECTIVES:

I. To record cytogenetics and International Myeloma Working Group (IMWG) response criteria at
diagnosis and prior to and following radiotherapy (RT).

OUTLINE:

Patients receive low-dose radiation therapy at consecutive business days 1 and 2 in the
absence of disease progression or unacceptable toxicity. Patients with no pain relief may
receive additional radiotherapy at 4 weeks following initial radiotherapy.

After completion of study treatment, patients are followed up at 2, 4, and 8 weeks and also
at 6 months.

Inclusion Criteria:

- Histologic diagnosis of multiple myeloma

- Painful bone metastasis (index lesion) that has a radiographic correlate

- Patient may have had any number of prior chemotherapy/immunotherapy regimens (changes
to systemic therapy or use of bisphosphonates for 4 weeks before and after RT are
allowed, but recording of these changes must be made so it can be accounted for)

- Eastern Cooperative Oncology Group (ECOG) 0-2

- Brief Pain Inventory (BPI) score >= 2

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Patients will be ineligible if the index lesion has received prior radiation therapy
or prior palliative surgery. Patients may have received prior palliative or primary
radiotherapy or surgery to other parts of the body, as long as the index lesion was
not in the prior radiation fields and has not received prior palliative surgery

- Patients will also be ineligible if there is pathologic fracture or impending fracture
at the site of the index lesion or planned surgical fixation of the bone at the index
lesion

- Patients with clinical or radiographic evidence of spinal cord or cauda equina
compression/effacement from the index lesion, and/or with index lesions located at the
skull base or orbital lesions

- Patients must not be pregnant
We found this trial at
6
sites
1983 Marengo St
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Leslie Ballas, MD
Phone: 323-409-4388
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Mohammad K. Khan
Phone: 404-778-3473
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Andrea K. Ng
Phone: 617-632-3400
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Leslie Ballas, MD
Phone: 323-409-4388
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1428 Madison Ave
New York, New York 10029
(212) 241-6500
Principal Investigator: Richard L. Bakst
Phone: 212-241-3545
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
?
mi
from
New York, NY
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Alireza F. Ghiam
Phone: 215-615-0559
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials